HYPNOTICS – Reducing & Stopping

Medicine Optimisation

The slides have been adapted from the NPC slide set available athttp://www.npc.nhs.uk/qipp/qipp_elearning/hypnotics_elearning.php

Practices to review and, where appropriate, revise prescribing of hypnotics to ensure that it is in line with national guidance

Options for local implementationNPC. Key therapeutic topics – Medicines management options for local implementation. Second update July 2011

Key questions

What are the recommendations on hypnotics?

What are the risks and benefits of hypnotics?

Do Z-drugs have advantages over benzodiazepine hypnotics?

How are we doing with prescribing?

How can people who want to withdraw from hypnotics be supported?

Problems associated with the long-term use of benzodiazepines

Adverse effects Drowsiness and falls Impairment in judgement and dexterity Increased risk of experiencing a road traffic accident Forgetfulness, confusion, irritability, aggression and paradoxical

disinhibition

Complications related to long-term use Depression Reduction in coping skills Tolerance and dependence

Dependence (one or more of following)

Patients gradually ‘need’ benzodiazepines to carry out normal day-to-day activities

Patients continue to take benzodiazepines although the original indication for the prescription is no longer relevant

Patients have difficulty stopping treatment or reducing dosage due to withdrawal symptoms

Short acting benzodiazepines may cause patients to develop anxiety symptoms between doses

Patients contact their doctor regularly to obtain repeat prescriptions Patients become anxious if the next prescription is not readily available Patients may increase the dosage stated in the original prescription Despite benzodiazepine therapy, patients may present with recurring

anxiety symptoms, panic, agoraphobia, insomnia, depression and an increase in physical symptoms of anxiety

Insomnia

A common disorder characterised by unsatisfactory sleep(sleep onset, sleep maintenance, early waking)

Predominantly a long-term disorder Before treatment rule out any potential causes of insomnia

External factors (light, noise, room temperature) Change in sleep environment (e.g. hotel) Physiological disturbance (e.g. shift work, daytime napping) Jet lag Acute illness Psychological factors (e.g. anxiety, depression, stressful life events) Substance misuse and drug withdrawal Stimulant use (e.g. caffeine, nicotine, OTC or prescribed medicines)

Perform sleep assessment (& anxiety rating)

Non-drug approachesClinical Knowledge Summaries. Last revised July 2009

CBT (Cognitive Behaviour Therapy)

Good sleep hygiene

Regular exercise

Relaxation

MHRA advice on benzodiazepines in insomnia(CSM. Curr Problems Pharmacovigilance. January 1988, No. 21)

Should be used only if insomnia is severe, disabling or subjecting the patient to extreme distress

Use lowest dose, for maximum of four weeks

Use intermittently, if possible, for insomnia

Taper off gradually

NICE guidance: newer hypnotics (Z-drugs)NICE technology appraisal 77, April 2004

No compelling evidence of a clinically useful difference between the Z-drugs and shorter-acting benzodiazepines from the point of view of their effectiveness, adverse effects, or potential for dependence or abuse

The drug with the lowest purchase cost should be prescribed

Switching from one of these hypnotics to another should only occur if a patient experiences adverse effects considered to be directly related to a specific agent. These are the only circumstances in which the drugs with the higher acquisition costs are recommended

Patients who have not responded to one of these hypnotic drugs should not be prescribed any of the others.

Hypnotics for insomniaSPCs for zopiclone, zolpidem, zaleplon; www.medicines.org.uk Zopiclone, Zolpidem

Short–term treatment of insomnia…in situations where the insomnia is debilitating or is causing severe distress for the patient

Long–term continuous use is not recommended

The duration of treatment should be limited to 4 weeks, including any tapering off

Zaleplon

A single course of treatment should not continue for longer than 2 weeks

What would happen to 13 people like you who take sleeping tablets for more than a weekGlass J, et al. BMJ 2005;331:1169

The hypnotic makes no difference to what happens to these 12 people. Their sleep improves, or doesn’t improve, just as if they had taken

placebo.

This person finds his/her sleep improves, who would not have done had he or she taken the

placebo

These 2 people have an adverse event, who would not have done had they taken the

placebo.

The hypnotic makes no difference to what happens to these 11 people.

They have adverse events, or don’t have adverse events, just as if they

had taken placebo.

Increased risk of road traffic accidents Gustavsen I, et al. Sleep Med 2008;9:818–22 www.npc.nhs.uk/rapidreview/?p=249

Cohort study of Norwegian drivers, aged 18 to 69 years

People prescribed zopiclone or zolpidem had double the risk of road traffic accidents (RTAs), compared with people not prescribed hypnotics

Standardised incidence ratio (SIR) of hypnotic use in previous 7 days, compared with no use:

Zopiclone or zolpidem — SIR 2.3 (95%CI 2.0 to 2.7)

Nitrazepam — SIR 2.7 (95%CI 1.8 to 3.9)

Flunitrazepam — SIR 4.0 (95%CI 2.4 to 6.4)

Absolute rates (per exposed 1000 person-years) of RTAs were:

about 5 to 9 accidents in groups treated with hypnotics

about 2 accidents in the group not exposed to hypnotics

Hip fractures and benzodiazepinesWagner AK, et al. Arch Intern Med 2004;164:1567–72

Incident relative risk of hip fracture with benzodiazepine (BZD) vs. no BZD use based on US claims data (194,071 person years of data, 1988-90): Any BZD exposure: 1.24 (95%CI 1.06 to 1.44) Long half-life BZD only: 1.13 (0.82 to 1.55) NS Short half-life high potency: 1.27 (1.01 to 1.59) Short half-life low potency: 1.22 (0.89 to 1.67) NS >1 BZD type: 1.53 (0.92 to 2.53) NS New BZD <16 days: 2.05 (1.28 to 3.28) New BZD 16–30 days: 1.88 (1.15 to 3.07) Continued BZD: 1.18 (1.03 to 1.35)

NS – No significant difference

Authors conclude: incidence of hip fracture appears to be associated with benzodiazepine use

Note: Different doses were not considered

Hypnotic QIPP data Q4 2012 -13(Cumbria, Northumbria, Tyne & Wear)

QIPP Prescribing ProfileJanuary to March 2013

Select Indicator:

Hypnotics ADQ/STAR PU, Cumbria,Northumb,Tyne & Wear Area TeamPeriod: January to March 2013

0.72 0.87 0.77 0.79 0.56 1.01 1.04 0.940.00

0.20

0.40

0.60

0.80

1.00

1.20

1.40

Ga

tesh

ea

d C

CG

Ne

wca

stle

No

rth

An

d E

ast

CC

G

Ne

wca

stle

We

stC

CG

No

rth

um

be

rla

nd

CC

G

So

uth

Tyn

esi

de

CC

G

Su

nd

erl

an

dC

CG

Cu

mb

ria

CC

G

No

rth

Tyn

esi

de

CC

G

Lower the Better

Hypnotics ADQ/STAR PU

Hypnotic QIPP data Q4 2012 -13(Cumbria Practices)

Hypnotics ADQ/STAR PU, Practice: A82077-Liverpool House Surgery Period : January to March 2013

QIPP Comparator Description

QIPP Prescribing ProfileJanuary to March 2013

Total number of average daily quantities (ADQs) for benzodiazepines (indicated for use as hypnotics) & “Z” drugs per Star-PU*.

Hypnotics ADQ/STAR PU, Practice: A82077-Liverpool House Surgery Period : January to March 2013

0.00

0.50

1.00

1.50

2.00

2.50

3.00

3.50

4.00

Wra

ysd

ale

Trin

ity H

se

The

Fam

ily

Warw

ick R

d

Fuseh

ill

Westc

roft H

se

Lo

wth

er

Ed

en

Ha

wkshe

ad

Asp

atr

ia

Gro

sve

no

r H

se

(W

ard

)

The

Cro

ft

Wig

ton

Orc

hard

Hse

Bru

nsw

ick H

se

Mansio

n H

se

Ca

theri

ne

St

Ne

lson S

t

Mary

port

Nu

twoo

d

Du

ke

St

Sp

en

ce

r S

t

Bri

dg

ega

te

Da

lto

n

Gro

sve

no

r H

se

(W

igm

ore

)

Lu

nesd

ale

Ca

stleh

ead

Ca

ldb

eck

Dis

ting

ton

Bu

rnett

Ed

ga

r

The

La

ke

s

Als

ton

So

lwa

y

Que

en S

t

Ha

ve

rthw

aite

Sill

oth

Bra

mp

ton

Du

ddo

n V

alle

y

Ulv

ers

ton (

Murr

ay)

Tem

ple

Sow

erb

y

Atk

inson

Pa

rk V

iew

De

rwent

Hse

Co

urt

Th

orn

The

Jam

es C

ochra

ne

Gle

nrid

din

g

Ha

rtin

gto

n S

t

Sta

tion H

se

Bir

be

ck

Ris

edale

St

Pa

uls

No

rwod

Lo

ngto

wn

Wate

rloo

Hse

Fellv

iew

Ca

pta

in F

rench

Sta

nw

ix

Se

db

erg

h

Ca

rtm

el

Jam

es S

t

Da

lsto

n

Liv

erp

ool H

se

Ulv

ers

ton (

Gra

ham

)

Ap

ple

by

Up

per

Ede

n

Arn

sid

e

Be

nth

am

Sh

ap

Ba

nk S

t

Ca

stleg

ate

Askam

Win

derm

ere

Ab

be

y R

d

Am

ble

sid

e

Pe

nin

sula

Kir

kosw

ald

St.

Mary

's

Se

ascale

Be

echw

ood

Sto

ne

leig

h

Gro

sve

no

r H

se

(F

rost)

Other Localities Selected Practice Selected Locality Upper Quartile Target England Average

Lower the Better

How can people who want to withdraw from hypnotics be supported? Older people are not always being given appropriate safety

warnings about taking these drugsIliffe S, et al. Aging Ment Health 2004;8:242–8

It is difficult to withdraw from hypnotic drugs

A letter from the GP can be effective in helping some to stopCormack MA, et al. Br J Gen Pract 1994;44:5–8

CBT can be helpful Morgan K, et al. HTA 2004:8(8)

See CKS guidance for further information

Published criteria for clinical audit are availableNICE TA77, April 2004; Shaw E, Baker R. J Clin Governance 2001;9:45–50

Key messages

Non-drug treatments should be considered and used routinely in all patients

1988 CSM advice re benzodiazepines still stands and is also applicable to Z-drugs

NICE guidance confirms that Z-drugs offer little or no advantage over benzodiazepines

However, overall prescribing of hypnotics is not decreasing Hypnotics should be used at lowest dose for max 4 weeks for

severe insomnia only Consider auditing hypnotic use and changing practice Resources exist for managing withdrawal

Suggested Practice Actions(1)

All prescribers must agree to be engaged and involved with the project Circulate to all prescribers the Welsh information pack, which containers

sample letters, sleep guides, reduction schedules etc.- email to all prescribers- electronic copy on surgery information folder - hard copy to be kept by medicine manager- easily accessible for reference- decide which parts are useful – print off?

Identify patients who receive hypnotics on repeat and acute- Medicine Mangers to search for last 12 months

Establish the demographics of patients- who to look at first?

Younger patients? (may be diverting supplies. If don’t stop now, may have many years of benzo use ahead of them)

Elderly patients? (at greater risks of falls, maybe on older medicines e.g. nitrazepam) Patients on high doses?

Middle aged group?

Suggested Practice Actions(2) Patient selection

- For each prescriber, a list of patients to be produced, based on which GP has seen the patient last or is most familiar with a patient. GPs can do ‘swaps’, if they wish! Need to make sure the numbers are divided fairly equally.- GP to go through the list, and eliminate anyone who has a genuine reason for being on the drug, or feel would be too difficult a challenge to start with.- GPs to identify one or two patients to call in for a medication review to discuss the issue, and start reducing the dose. (method to be decided)

Each month, one or two more patients selected. This is a gradual process - the numbers will build up slowly but steadily, depending on the workload created by withdrawing patients. Some patients may be deemed too difficult to stop completely but even a reduction in dose or a switch to a shorter acting drug is preferable to doing nothing.

The reduction method should be discussed and tailored to each individual patients needs converting to equivalent diazepam dose, and reducing slowly reducing the dose of the drug gradually reducing the number of tablets supplied for a set time period i.e. having

drug free nights e.g. 25 tablets lasting 28 days etc. The patient needs to see the same GP during the reduction schedule, especially if

the patient is requesting the dose to be increased back up.

Suggested Practice Actions(3)

New Patients prescribed hypnotics- only prescribe if absolutely clinically essential - seven days supply only, as an acute script (Good Practice)- label as ‘ one at night, if required’- zopiclone = Lothian Joint Formulary 2nd choice (1st choice = no treatment)- give patient ‘Good sleep guide/Good relaxation guide’- no repeat prescriptions for new patients

At prescribing meetings within the practice, suggest analysing prescribing of hypnotics within the last 3 months to determine if any patients have been commenced and continued on hypnotics, and the reasons why.

Transferred patients- Any new patients registering with the practice from another surgery on hypnotics will have their medication discussed and reviewed at their initial consultation.

The message that the patient needs to reduce, and eventually stop, their use of these drugs should be re-enforced at every opportunity.

Involvement of the drug and alcohol service should be considered.

Support Material

Cumbria GP Practice guide

Welsh Education Pack

Presentation

Hypnotic Academic Detailing Aid

The Good Sleep Guide

The Good Relaxation Guide

Patient letters

Reduction Protocols

Community Pharmacy support

Prepared byFiona Gunston, Lynne Palmer, Judi Matthews & Jim Loudon

Medicines Optimisation Pharmacists for NHS Cumbria Clinical Commissioning GroupNorth of England Commissioning Support (NECS)

Using slides and notes provided by NPC (National Prescribing Centre)